Opportunistic infections (OI) following monoclonal antibody treatment

摘要: 2562 Background: During recent years the therapeutic indications of monoclonal antibodies are on increase. Most immunosuppressants. Thus, successes accompanied by an increase serious infections. Methods: We systematically reviewed literature OI following antibody treatment with alemtuzumab and rituximab. Results: Between 1996 2004, were reported in 17 articles. A total 992 patients (pts) treated, these 409 pts (41.2%) alemtuzumab, 535 (53.9%) rituximab, 48 (4.9%) both. Optional prophylaxis viral infections was 8 articles (404 (40.7%)), optional Pneumocytis carinii pneumonia (PCP) 9 (435 (43.9%)). The overall number diagnosed 299 (30.1%). Etiologies distributed as follows: 44 (14.7%) bacterial infections, 26 (8.7%) fungal 11 (3.7%) protozoal (3%) 100 (33.4%) reactivations, 109 (36.5%...